表紙
市場調査レポート

世界のナノメディシン市場およびパイプラインの分析:2015年

Global Nanomedicine Market & Pipeline Insight 2015

発行 KuicK Research 商品コード 325476
出版日 ページ情報 英文 330 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
世界のナノメディシン市場およびパイプラインの分析:2015年 Global Nanomedicine Market & Pipeline Insight 2015
出版日: 2015年03月05日 ページ情報: 英文 330 Pages
概要

ナノテクノロジーに基づく数多くの医薬品、デバイス、センサー、チップが臨床開発の各段階にありますが、上市済みの製品は少なく、適応症、市場規模ともに限定的です。この臨床パイプラインは年々活発化し、医薬品事業者も新たなイニシアチブに取り組んでいますが、製品の市場投入の遅れは市場の停滞をもたらします。今後は研究開発のペースアップが求められています。

当レポートでは、世界のナノメディシン市場およびパイプラインの動向について調査し、ナノメディシンの概要、メカニズム、成長推進因子と課題、パイプラインのフェーズ別の動向、上市済みナノメディシンの概要、将来の展望、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション:ナノメディシン

第2章 ナノメディシンのメカニズム

第3章 世界のナノメディシン市場の見通し

  • 現在の市場シナリオ
  • 世界におけるナノメディシンのパイプラインの概要

第4章 世界のナノメディシン市場の力学

  • 市場に好意的なパラメーター
  • 上市における課題

第5章 世界のナノメディシン市場:将来の展望

第6章 世界のナノメディシンパイプライン:企業・適応症・フェーズ別

  • 研究
  • 前臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第II/III相
  • 第III相

第7章 上市済みナノメディシン:企業・適応症別

第8章 開発延期・中止のパイプライン

  • 開発報告なし
  • 中止
  • 延期

第9章 競合環境

  • Abraxis BioScience
  • Access Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Amgen
  • Arrowhead Research
  • BIND Therapeutics
  • Cadila Healthcare
  • Celegen Corporation
  • Celsion Corporation
  • Genzyme Corporation
  • Merck
  • NanoCarrier
  • 日本化薬
  • Nanobiotix
  • Novavax
  • Pfizer
  • Roche
  • Samyang
  • Sanofi
  • 武田薬品工業

図表一覧

目次

Nanomedicines or nanotherapeutics is an emerging field in which nanotechnology principles are used to design and develop better therapeutics having high safety and efficacy profiles. It is a multidisciplinary approach utilizing knowledge from allied fields like biotechnology and pharmacology in drug development program. Novel modalities for cancer treatment, targeted drug delivery, biosensors, imaging, delivery vehicles and diagnostic methods are being actively investigated by pharmaceutical companies. They have been widely accepted among physicians and patients due to which novel products are expected to generate significant revenues. Several other benefits have yet to be discovered which will further help in the extension of this field. With time, more technological advancements are expected to be made resulting in development better of nanomedicines for several disease indications.

Pharmaceutical companies are developing better drug delivery vehicles with the help of nanotechnology. Unspecificity causes undue wastage of drug, potency reduction and undue side effects during therapy. This problem become serious when patient is suffering from life threatening disease like cancer and use of chemotherapy is a part of therapeutic regime. Easy modification, customizability and cost of product are expected to be the main reasons determining the commercial success besides their pharmacological benefits. Huge investments in research and development are expected to help in identifying useful nanoparticles based drug delivery vehicles. Several methods have been identified by pharmaceutical companies in past few years and many more are being under development.

Use of nanomedicines for cancer is one of the largest and most developed segments containing several products in both market and clinical pipeline. Nanotechnology based liposome products could be observed as one of the most advance segment among oncology medicines. For instance, Doxil by Ortho pharmaceuticals was among first approved cancer nanomedicines by US FDA in 1995 for treating AIDS-related Kaposi's sarcoma. DaunoXome by Galen Ltd is also a liposomal formulation used for the treatment of HIV relates Kaposi sarcoma and clinical trials for utilization of this medicine for leukemia is also under investigation. More products are at different stages of clinical trials which will be introduced in global market in coming years.

Numerous nanotechnology based medicines, devices, sensors and chips are at various phases of clinical development. Only limited products are in market for few indications which is mainly responsible for small market size as compared to mainstream medicines. Their clinical pipeline is becoming strong every year and new initiatives are being taken by pharmaceutical companies but as such number of market introductions is less. Without immediate commercialization of such products their market size will be limited which will cause stagnancy. In order to overcome these barriers, pace of research and development along with market introduction has to be increased in coming time. It would help in generating significant revenues but it will take few years for nanomedicines to get recognition as mainstream medicines. But, the pace at which they are growing shows optimistic future of nanomedicines and associated medical technologies.

“Global Nanomedicine Market & Pipeline Insight 2015” Report Highlights:

  • Global Nanomedicine Market Outlook
  • Global Nanomedicine Market Dynamics
  • Global Nanomedicine Clinical Pipeline by Company, Indication & Phase
  • Global Nanomedicine Clinical Pipeline: 144 Nanomedicines
  • Marketed Nanomedicines: 13 Nanomedicines
  • Nanomedicine Patent Analysis
  • Global Nanomedicine Market Future Prospects

Table of Contents

1. Introduction to Nanomedicine

2. Mechanism of Nanomedicine

3. Global Nanomedicine Market Outlook

  • 3.1. Current Market Scenario
  • 3.2. Global Nanomedicine Pipeline Overview

4. Global Nanomedicine Market Dynamics

  • 4.1. Favorable Market Parameters
  • 4.2. Market & Commercialization Challenges

5. Global Nanomedicine Market Future Prospects

6. Global Nanomedicine Clinical Pipeline by Company, Indication & Phase

  • 6.1. Research
  • 6.2. Preclinical
  • 6.3. Phase-I
  • 6.4. Phase-I/II
  • 6.5. Phase-II
  • 6.6. Phase-II/III
  • 6.7. Phase-III

7. Marketed Nanomedicine by Company & Indication

8. Suspended & Discontinued Nanomedicine Clinical Pipeline

  • 8.1. No Development Reported
  • 8.2. Discontinued
  • 8.3. Suspended

9. Competitive Landscape

  • 9.1. Abraxis BioScience
  • 9.2. Access Pharmaceuticals
  • 9.3. Alnylam Pharmaceuticals
  • 9.4. Amgen
  • 9.5. Arrowhead Research
  • 9.6. BIND Therapeutics
  • 9.7. Cadila Healthcare
  • 9.8. Celegen Corporation
  • 9.9. Celsion Corporation
  • 9.10. Genzyme Corporation
  • 9.11. Merck
  • 9.12. NanoCarrier
  • 9.13. Nippon Kayaku
  • 9.14. Nanobiotix
  • 9.15. Novavax
  • 9.16. Pfizer
  • 9.17. Roche
  • 9.18. Samyang
  • 9.19. Sanofi
  • 9.20. Takeda Pharmaceutical

List of Figures:

  • Figure 1-1: Benefits of Nanotechnology
  • Figure 1-2: Uses of Nanomedicine
  • Figure 1-3: Benefits of Nanomedicine
  • Figure 2-1: Required Features of Nanomolecule
  • Figure 2-2: Benefits of Nanotechnology Based Drug Delivery Systems
  • Figure 2-3: Nanotechnology Based Drug Delivery Systems
  • Figure 2-4: Mechanism of Abraxane
  • Figure 2-5: Mechanism of Doxil
  • Figure 3- 1: Global Nanomedicine Market (US$ Billion), 2013-2020
  • Figure 3- 2: Global Nanomedicine Pipeline by Phase (%), 2015
  • Figure 3- 3: Global Nanomedicine Pipeline by Phase (Number), 2015
  • Figure 3- 4: No Development Reported in Nanomedicine Pipeline by Phase (%), 2015
  • Figure 3- 5: No Development Reported in Nanomedicine Pipeline by Phase (Number), 2015
  • Figure 3- 6: Discontinued Nanomedicine Pipeline by Phase (%), 2015
  • Figure 3- 7: Discontinued Nanomedicine Pipeline by Phase (Number), 2015
  • Figure 3- 8: Suspended Nanomedicine Pipeline by Phase (Number), 2015
  • Figure 3- 9: Suspended Nanomedicine Pipeline by Phase (%), 2015
  • Figure 4-1: Drivers for Global Nanomedicine Market
  • Figure 4-2: Global Nanomedicine Market & Commercialization Challenges
  • Figure 9-1: Arrowhead Research Corporation Clinical Pipeline
  • Figure 9-2: NanoCarrier Clinical Pipeline
Back to Top